Loading
A phase 1 trial of MT-601 run by Marker Therapeutics, Inc., now recruiting.
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma is a phase 1 interventional study registered as NCT05798897 by Marker Therapeutics, Inc., with 79 participants planned, started 2023-01-02. Conditions recorded: Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult and Hodgkin's Lymphoma, Relapsed, Adult. Interventions recorded: MT-601.
Shares Marker Therapeutics, MT-601 and the tag pipeline.
Shares Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Hodgkin lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/